JPRN-UMIN000012208已完成2 期
A phase II trial of pertuzumab and trastuzumab in combination with capecitabine in patients with metastatic breast cancer who received prior trastuzumab combination chemotherapy. - A phase II trial of pertuzumab and trastuzumab in combination with capecitabine in patients with metastatic breast cancer who received prior trastuzumab combination chemotherapy.
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 70years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1) History of hypersensitivity reaction 2) Brain metastasis 3) Pleural effusion, ascites, and pericardial fluid requiring treatment 4) Active another cancer 5) Active infection 6) Other severe complications, such as heart failure, interstitial pneumonia and renal failure with clinically problem 7) Required treatment with steroid 8) Pregnant or possibility pregnancy or nursing women 9) Mental disorder which become problem on clinical practice 10) Physician judged improper to entry this trial
研究者
相似试验
暂停
不适用
Phase II trial of pertuzumab and trastuzumab in combination with S-1 for patients with HER2-positive metastatic breast cancerBreast cancerJPRN-UMIN000024477Kurume University School of Medicine32
已完成
2 期
Phase II Trial of Pertuzumab plus Trastuzumab plus Docetaxel for HER2-Positive Metastatic Breast Cancer that Progressed During Prior Trastuzumab TherapyHER2-Positive Metastatic Breast CancerJPRN-UMIN000012452Chiba Youth Breast Oncology Research Group (CYBORG)35
招募中
2 期
A Phase II study of pertuzumab+trastuzumab+capecitabine in Patients with taxans and trastuzumab refractory for advanced or recurrent breast cancerHER2-positive metastatic breast cancerJPRN-UMIN000012030Saitama Breast Cancer Clinical Study Group30
进行中（未招募）
1 期
A randomized phase II trial of pertuzumab in combination with trastuzumab with or without chemotherapy, both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer - PERNETTAEUCTR2012-002556-17-FRICANCER208
已完成
2 期
A randomized phase II trial of pertuzumab in combination with trastuzumab with or without chemotherapy, both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer10006291Breast cancerNL-OMON44863ICANCER26